🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔹What is the optimal therapeutic dose for immune checkpoint inhibitors? 🔹What is the maximum tolerated dose? 🔹What is the minimum effective dose? 🔹Are dose-response curve and dose-side-effect curve linear? 🔹Why is it used as a flat-dose and not per kilogram? 1/..

Meningioma Grading Will Never Be the Same: 🔑 Takeaways from cIMPACT-NOW Update 8 OncoAlert For oncologists & radiation oncologists: here’s what you need to know about the molecular era of meningiomas🧵(1/14)

Join us now for the Common sense oncology plenary session . We live! Abeid Athman (Omar). Fidel Rubagumya , MD, MMed, MPH

It was my pleasure to meet the shining Star Andrea Anampa-Guzmán (she/ella) during the ASCO - AIOM Clinical Research Course training in Rome, Italy. The world has become a global village. Massimo Di Maio

#ESMOBreast25 is next month. Love this "digestible" breast only meeting with the benefits of extra interaction with all of our international colleagues. Registration: esmo.org/meeting-calend… Program: cslide.ctimeetingtech.com/coasis_21219/a… #bcsm ESMO - Eur. Oncology G Curigliano MD PhD FabriceAndre

🚨 Hiding in plain sight: NUT carcinoma is a highly aggressive, underrecognized subtype of SCC in lung & head/neck cancer. ✅Early diagnosis is critical, yet misclassification persists. ✅Time to rethink its place in SCC taxonomy. Reclassification could accelerate therapeutic

We’re incredibly proud of AACR President Lillian L. Siu Dr. Pat LoRusso for her unwavering support of all patients with cancer and work to advance cancer research, clinical trials, and treatments. #AACR25 Roy Herbst Friends of Cancer Research Abeid Athman (Omar). Smilow Cancer Hospital AACR Yale School of Medicine Yale New Haven Hosp

It was a great honour to be invited to the AACR President's Dinner by the AACR president Dr. Patricia LoRusso at the ongoing #AACR25. Many thanks for taking her precious time to introduce me to different KOL. G Curigliano MD PhD Toni Choueiri, MD

An outstanding and emotional presentation by AACR President Lillian L. Siu Dr. LoRusso during the Presidential address. #AACR25 Yale Cancer Center AACR

Delighted to have met the father of tumour agnostic Oncology Vivek Subbiah, MD and the ADC guru Raffaele Colombo at the #AACR25. #UnitedByScience. Paolo Tarantino

We can't let our junior faculty the ability not to dream - Pat LoRusso, the outgoing AACR president. #AACR25 G Curigliano MD PhD Raffaele Colombo Vivek Subbiah, MD

10y results of FAST FORWARD (adjuvant #breastcancer RT) trial presented at #ESTRO25 by AM Brunt. Compared to 40Gy/15, 26Gy/5: 1. Non inf for IBR (even superior?) 2. Similar recurrence free interval, breast cancer interval, OS 3. No diff in PRO or toxicity Clearly 26/5 SOC for

🚨Birgitte Offersen reports on SKAGEN-1 trial of hypofractionation (40/15 vs 50/25) #ESTRO25 1. Safe: similar lymphedema 2. Effective: similar locoregional and distance recurrence, OS BUT increased #breastcancer mortality, across subgroups & w/o explanation. Discussions to follow…

🚨10y results of HYPO RT PC at #ESTRO25 Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT 1. Non inferior for FFS (even better?) 2. Similar bPFS, DMFS, ADT use, OS 3. Similar GU/GI tox (except transient flare at 1y for UHF)

"De-escalation is not omission - it is optimisation. It is not giving less, but giving better, tailored to each patient and supported by evidence" Icro Meattini great discussant👏🏻 #ESTRO25 Late Breaking Papers

#ESTRO25 - Day 2 🌟 Joint ESTRO-ESMO: Integration of novel systemic therapies into radiotherapy: Why, when and how? ▶️ Intracranial irradiation and new systemic therapies: Tips and tricks by Giuseppe Minniti #BreastCancer @ESMO ESTRO Icro Meattini OncoAlert

SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03. Convenient Fast Similar outcomes than post op brachy Mostly VMAT homogeneous plans #ESTRO25

I’m SO delighted to finally see the STAR-TREC data reported 🤩 #ESTRO25 Short course RT vs chemorad for organ preservation in early stage rectal cancer 61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad! #radonc #rectalcancer

Beautiful discussion by Kevin Kalinsky, MD, MS, FASCO -Low TIL &N+ assoc w/ worse outcome in pts with pCR - High ROR identified in about 1/4 of pts with low RS #ESMOBreast25 ESMO - Eur. Oncology

Brilliant discussion by Javier Cortes MD PhD on APHINITY If adjuvant treatments decrease distant events, is OS benefit really needed to be seen to start using therapies? APHINITY took 11.3 yrs to be able to see OS benefit. #ESMOBreast25 ESMO - Eur. Oncology